GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » Notes Receivable

Greenyn Biotechnology Co (ROCO:6846) Notes Receivable : NT$0.0 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co Notes Receivable?

Greenyn Biotechnology Co's Notes Receivable for the quarter that ended in Mar. 2024 was NT$0.0 Mil.


Greenyn Biotechnology Co Notes Receivable Historical Data

The historical data trend for Greenyn Biotechnology Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co Notes Receivable Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - - -

Greenyn Biotechnology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Greenyn Biotechnology Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Greenyn Biotechnology Co Notes Receivable Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenyn Biotechnology Co (ROCO:6846) Business Description

Traded in Other Exchanges
N/A
Address
5th Floor, No 43 Keya Road, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines